Lupin rises to all-time high, climbs 3% as co acquires Huminsulin from Eli Lilly

The global pharma major had already been marketing the Huminsulin range of products through distribution and promotion agreements with Eli Lilly. Its marketing efforts were focused on products, including Insulin Human, comprising Huminsulin R, Huminsulin NPH, Huminsulin 50/50 and Huminsulin 30/70, the company said in a press release dated December 30.

“This acquisition is strategic to our ongoing efforts to expand our diabetes portfolio and provide highquality, affordable health care to our patients. It reinforces our unwavering commitment to combating diabetes and providing comprehensive care,” the Managing Director of Lupin, Nilesh Gupta commented.

“Lupin has been at the forefront of providing holistic diabetes care to patients. This acquisition further strengthens our diabetes portfolio and enables us to offer a broad range of human insulin options to millions of patients, thereby helping them lead healthier lives,” , Rajeev Sibal, the President of Lupin’s India Region Formulations, said regarding the acquisition.

Past stock performance

The stock was trading at ₹2,368.50, up 2.47% at around 1:18 pm on the NSE.

The scrip rallied 9.81 over the past five days and surged 14.49% over the past month on the National Stock Exchange (NSE).

The scrip has galloped 46.35% over the past six months.

Almost a year ago, on January 1, the company was trading at a 52-week-low low of ₹1,308.65. Since then, the company has gained about 80.15% on the NSE.

Lupin had a total market cap of ₹1,08,029.50 crore as of December 31, 2024, according to NSE.

About the Huminsulin range

The Huminsulin line of products is used for the treatment of type 1 and type 2 diabetes mellitus and to improve blood sugar control in adults and children.

“Insulin treatment is the cornerstone of type 1 diabetes management and often becomes necessary over time in type 2 diabetes as the disease progresses. There is a significant Indian population affected with diabetes for both Type 1 and Type 2 Diabetes Mellitus, where Insulin Human is prescribed for management along with other concomitant therapies,” the press release added.

About the company

Lupin is a multinational pharmaceutical company headquartered in Mumbai. It develops and commercialises a diversified range of more than 1,000 products in over 100 markets, including India, the US, South Africa, and the Asia Pacific, Latin America, Europe, and Middle East regions.